Overview
- The Osaka Cancer Registry study, published Monday in Cancer, reports a sharp rise in therapy‑related acute myeloid leukemia over three decades.
- Incidence increased from 0.13 to 0.36 cases per 100,000 people between 1990 and 2020, and the share of all AML cases rose from 4.4% in the 1990s to 8.2% after 2010.
- The registry recorded 9,841 AML cases, with 636 patients, or 6.5%, classified as therapy‑related, typically at a median age of 69 about five years after first cancer treatment.
- The first cancers linked to these cases shifted over time as blood cancers stayed most common while links grew for breast, head‑and‑neck, and lung cancers and fell for gastric cancer.
- The authors call for tighter long‑term follow‑up and targeted studies of treatment risks, noting mixed national trends reported in Denmark and Sweden.